CYP2D6 genotypes in association with steady state plasma concentrations of active metabolites of tamoxifen in patients with breast cancer.

被引：0
|
作者：
Lim, H.
Lee, H.
Lee, K.
Lee, E.
Jang, I.
Ro, J.
机构：
[1] Natl Canc Ctr, Res Inst & Hosp, Gyeonggi, South Korea
[2] Natl Canc Ctr, Gyeonggi, South Korea
[3] Seoul Natl Univ, Coll Med, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：36S / 36S
页数：1
相关论文
共 50 条
  • [1] CYP2D6 Genotype Predicts Plasma Concentrations of Tamoxifen Metabolites in Ethiopian Breast Cancer Patients
    Ahmed, Jemal Hussien
    Makonnen, Eyasu
    Fotoohi, Alan
    Aseffa, Abraham
    Howe, Rawleigh
    Aklillu, Eleni
    CANCERS, 2019, 11 (09)
  • [2] CYP2D6 and ESR genotypes in adjuvant tamoxifen treatment for early breast cancer.
    Kim, K.
    Jung, K. H.
    Ahn, J.
    Kim, S.
    Kim, H. J.
    Ko, B.
    Lee, J. W.
    Son, B. H.
    Ahn, S.
    Gong, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (27)
  • [3] Relationship between CYP2D6 and SULT1A1 genotypes and serum concentrations of tamoxifen and its metabolites during steady state treatment in breast cancer patients
    Gjerde, J
    Hauglid, M
    Breilid, H
    Lundgren, S
    Varhaug, JE
    Kisanga, ER
    Mellgren, G
    Steen, VM
    Lien, EA
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S236 - S237
  • [4] Impact of CYP2D6 genotypes on the steady-state plasma concentrations of paroxetine in Japanese psychiatric patients
    Ueda, M
    Hirokane, G
    Morita, S
    Okawa, M
    Shimoda, K
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2004, 19 (03) : 178 - 178
  • [5] Dose adjustment of tamoxifen based on CYP2D6 genotypes in Japanese breast cancer patients
    不详
    PHARMACOGENOMICS, 2012, 13 (06) : 647 - 648
  • [6] The influences of adherence to tamoxifen and CYP2D6 pharmacogenetics on plasma concentrations of the active metabolite (Z)-endoxifen in breast cancer
    Casali da Rocha, Jose Claudio
    Nardin, Jeanine M.
    Schroth, Werner
    Almeida, Thais A.
    Muerdter, Thomas
    Picolotto, Solange
    Vendramini, Evelyn C. L.
    Hoppe, Reiner
    Kogin, Jenifer P.
    Miqueleto, Diandra
    Moraes, Silvia D. R.
    Schwab, Matthias
    Pecoits-Filho, Roberto F.
    Brauch, Hiltrud
    CANCER RESEARCH, 2020, 80 (04)
  • [7] The Influences of Adherence to Tamoxifen and CYP2D6 Pharmacogenetics on Plasma Concentrations of the Active Metabolite (Z)-Endoxifen in Breast Cancer
    Nardin, Jeanine Marie
    Schroth, Werner
    Almeida, Thais Abreu
    Muerdter, Thomas
    Picolotto, Solane
    Lima Vendramini, Evelyn Castillo
    Hoppe, Reiner
    Kogin, Jenifer Primon
    Miqueleto, Diandra
    Robaskievicz de Moraes, Silvia Dark
    Schwab, Matthias
    Pecoits-Filho, Roberto Flavio
    Brauch, Hiltrud
    Casali-da-Rocha, Jose Claudio
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2020, 13 (02): : 284 - 292
  • [8] Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes
    Madlensky, L.
    Natarajan, L.
    Tchu, S.
    Pu, M.
    Mortimer, J.
    Flatt, S. W.
    Nikoloff, D. M.
    Hillman, G.
    Fontecha, M. R.
    Lawrence, H. J.
    Parker, B. A.
    Wu, A. H. B.
    Pierce, J. P.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 (05) : 718 - 725
  • [9] Frequency of CYP2D6*10 genotypes in Pakistani breast cancer patients taking adjuvant tamoxifen
    Nazir, Nusrat
    Waheed, Akbar
    Farhat, Kulsoom
    Ismail, Muhammad
    Mansoor, Qaisar
    JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION, 2016, 66 (12) : 1554 - 1558
  • [10] Association of CYP2D6 genotype and tamoxifen metabolites with breast cancer recurrence in a low-dose trial
    DeCensi, Andrea
    Johansson, Harriet
    Helland, Thomas
    Puntoni, Matteo
    Macis, Debora
    Aristarco, Valentina
    Caviglia, Silvia
    Webber, Tania Buttiron
    Briata, Irene Maria
    D'Amico, Mauro
    Serrano, Davide
    Guerrieri-Gonzaga, Aliana
    Bifulco, Ersilia
    Hustad, Steinar
    Soiland, Havard
    Boni, Luca
    Bonanni, Bernardo
    Mellgren, Gunnar
    NPJ BREAST CANCER, 2021, 7 (01)
12345